Amgen, Takeda Acquisition Targets Involve Limited Exposure To Medicare – And Price Controls
Executive Summary
Prospect of Medicare price setting under the Inflation Reduction Act was factored into the rationale for two recent and notable deals for products with limited exposure to the government insurance program.
You may also be interested in...
IRA Implications Will Factor Significantly In Deal Strategy In 2023
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Turbulent weather matches sentiment about the year ahead, with investors looking for reassurance on the IRA, deal-making and growth strategy from big pharma. Updates from J&J, Biogen, BMS, Merck and more.
Medicare Drug Pricing Casts A Cloud Over J.P. Morgan’s Opening Day
Inflation Reduction Act means that industry ‘will have to adjust’ to new market realities, especially for small molecule drugs.